Articles

As pharmacists’ responsibilities extend beyond dispensing medications to include advanced patient-centered services, many already meet the definition of nonphysician provider under Medicare Part B, yet they are often not reimbursed for their services. Read More ›

In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy. Read More ›

Despite remarkable advancements in the treatment of cancer through the use of targeted agents and immunotherapy, outcomes are still varied, and, for some patients, these regimens provide only a short-term answer. Read More ›

The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive. Read More ›

The Journal of Hematology Oncology Pharmacy is pleased to provide readers the Second Annual Oncology Pharmacy Guide to New FDA Approvals. The goal of this Guide is to offer payers, oncology/hematology pharmacists, and other healthcare stakeholders a comprehensive review of novel oncology/hematology drugs that were approved by the US Food and Drug Administration (FDA) in the previous year. Read More ›

In the United States, an estimated 12,310 individuals will be diagnosed with soft-tissue sarcoma in 2016, and 4990 will die of the disease. Read More ›